A Randomized, Double-blind, Multicenter Phase II Trial to Compare the Immunogenicity and Safety of a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN) Smallpox Vaccine in Vaccinia-naive Healthy Subjects

Trial Profile

A Randomized, Double-blind, Multicenter Phase II Trial to Compare the Immunogenicity and Safety of a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN) Smallpox Vaccine in Vaccinia-naive Healthy Subjects

Completed
Phase of Trial: Phase II

Latest Information Update: 13 May 2015

At a glance

  • Drugs Smallpox vaccine (Primary)
  • Indications Smallpox
  • Focus Pharmacodynamics
  • Sponsors Bavarian Nordic
  • Most Recent Events

    • 13 May 2015 Primary endpoint 'Geometric Mean Titers (GMTs) measured by ELISA' has been met, according to a Bavarian Nordic media release.
    • 22 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 13 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top